M2ES 7.5mg

M2ES 15mg

M2ES 30mg

M2ES 60mg

Su LI, PhD

Su Li, PhD

LI Zhang, master

Li Zhang, master

This study is dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.

This study is a Phase I dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

Pharmacokinetic (PK) behavior of different doses of M2ES in Subjects With Advanced Solid Tumors

Protgen Ltd

Guodong Chang

Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

M2ES

M2ES 60mg IV D1,8,15,22 every 28days a cycle

Long CHENG, master

Fei WU, master

Jihui HAO, MD

Shunchang JIAO, MD

The purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.

To evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.We star with the dose M2ES 15mg,then escalate to 30mg 45mg 60mg,to find the recommended dose in clinic practise.

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Guodong CHANG

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors	NCT01226030	Advanced Solid ...	M2ES 7.5mg M2ES 15mg M2ES 30mg M2ES 60mg	18 Years - 65 Years	Protgen Ltd
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors	NCT01226030	Advanced Solid ...	M2ES 7.5mg M2ES 15mg M2ES 30mg M2ES 60mg	18 Years - 65 Years	Protgen Ltd
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure	NCT01219192	Pancreatic Canc...	M2ES M2ES M2ES M2ES 60mg	18 Years -	Protgen Ltd

Spots Global Cancer Trial Database for m2es 60mg

Every month we try and update this database with for m2es 60mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for m2es 60mg

Every month we try and update this database with for m2es 60mg cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for m2es 60mg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.